Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.